<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Aim</h3><p>The purpose of this study is to present the first Romanian case-series of patients with heart failure with reduced ejection fraction (HFrEF), supported with the newest generation of cardiac contractility modulation (CCM) device.</p></sec>
<sec><h3>Methods and results</h3><p>16 patients (15 men), aged 66.6±7.49 years, were supported with OPTIMIZER® smart IPG CCMX10 device and followed-up for an average duration of 385.75±326.32 days. The etiology of HF was ischemic in 13 patients (81%), 8 patients (50%) had atrial fibrillation, mean creatinine clearance value was 55.8±13.87 ml/min, and 5 patients (31,2%) had diabetes mellitus. All patients were supported with an implanted cardio verter-defibrillator (ICD), while 5 patients (31.2%) had cardiac resynchronization therapy (CRT) on top. The pharma cological treatment has been optimized in all patients. Six months after implantation, the LVEF has increased from 25.93%±6.21 to 35.5%±4.31 (p=0.00002), NYHA class improved from 3.18±0.4 to 1.83±0.38 (p&lt;0.0001), and exercise tolerance evaluated with 6-minute walking test (6MWT) increased (from 321.87±70.63m to 521.41±86.43m; p&lt;0,00001). Three patients (18,7%) died during the follow-up period after 48, 108 and 545 days (one non-cardiac death).</p></sec>
<sec><h3>Conclusions</h3><p>Cardiac contractile therapy is a feasible, safe, and useful therapy for patients with HFrEF whose symptomatology is not improved with optimal standard therapy.</p></sec>
</abstract>

AimThe purpose of this study is to present the first Romanian case-series of patients with heart failure with reduced ejection fraction (HFrEF), supported with the newest generation of cardiac contractility modulation (CCM) device.
Methods and results16 patients (15 men), aged 66.6±7.49 years, were supported with OPTIMIZER® smart IPG CCMX10 device and followed-up for an average duration of 385.75±326.32 days. The etiology of HF was ischemic in 13 patients (81%), 8 patients (50%) had atrial fibrillation, mean creatinine clearance value was 55.8±13.87 ml/min, and 5 patients (31,2%) had diabetes mellitus. All patients were supported with an implanted cardio verter-defibrillator (ICD), while 5 patients (31.2%) had cardiac resynchronization therapy (CRT) on top. The pharma cological treatment has been optimized in all patients. Six months after implantation, the LVEF has increased from 25.93%±6.21 to 35.5%±4.31 (p=0.00002), NYHA class improved from 3.18±0.4 to 1.83±0.38 (p<0.0001), and exercise tolerance evaluated with 6-minute walking test (6MWT) increased (from 321.87±70.63m to 521.41±86.43m; p<0,00001). Three patients (18,7%) died during the follow-up period after 48, 108 and 545 days (one non-cardiac death).
ConclusionsCardiac contractile therapy is a feasible, safe, and useful therapy for patients with HFrEF whose symptomatology is not improved with optimal standard therapy.

Cardiac Contractility Modulation Therapy for Heart Failure – First Romanian Experience

Romanian Journal of Cardiology

This work is licensed under the Creative Commons Attribution 4.0 International License.

AimThe purpose of this study is to present the first Romanian case-series of patients with heart failure with reduced ejection fraction (HFrEF), supported with...

Parameter	Baseline	At 6 months	p
NYHA class	3.187±0.4	1.08±0.38	p < 0.0001
LVEF (%)	25.93±6.21	35.5±4.31	p = 0.00002
6MWT (m)	321±87	521.41±86.38	p < 0.0001

Baseline characteristics	Value
Age (year)	66.5±7.49
Male	93.7%
Ischemic disease	81%
Revascularization therapy	68.7%
Hypertension	19%
Diabetes mellitus	31%
Atrial fibrillation	50%
LVEF (%)	25.93±6.21
6MWT (m)	321.87±70.63

Cardiac Contractility Modulation Therapy for Heart Failure – First Romanian Experience

Article Category: Original Article

Data publikacji: 05 maj 2022

Zakres stron: 609 - 614

DOI: https://doi.org/10.47803/rjc.2021.31.3.609

Słowa kluczowe
heart failure, cardiac contractility modulation, cardiac devices, device implantation

© 2021 Diana Tint et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Figure 1

Figure 2

Figure 3

Figure 4

Clinical and hemodynamic parameters at baseline and at 6 months

Baseline characteristics

Cardiac Contractility Modulation Therapy for Heart Failure – First Romanian Experience

Article Category: Original Article

Data publikacji: 05 maj 2022

Zakres stron: 609 - 614

DOI: https://doi.org/10.47803/rjc.2021.31.3.609

Słowa kluczoweheart failure, cardiac contractility modulation, cardiac devices, device implantation

© 2021 Diana Tint et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Figure 1

Figure 2

Figure 3

Figure 4

Clinical and hemodynamic parameters at baseline and at 6 months

Baseline characteristics

Słowa kluczowe
heart failure, cardiac contractility modulation, cardiac devices, device implantation